Ganymede Bio, the cloud infrastructure supplier purpose-built for the life sciences and manufacturing industries, has introduced a $12.75 million collection A funding spherical, led by Caffeinated Capital. 

This follows a $2.9 million seed spherical accomplished earlier this yr, bringing the entire to greater than $15.6 million. Based in 2022, Ganymede Bio has exceeded $1 million in income commitments, with shoppers starting from early-stage biotechs to giant, established biopharmaceutical firms.

“Scientific software program, particularly for biotechs, is 10 to twenty years behind different industries,” mentioned Nathan Clark, co-founder of Ganymede Bio. 

“We’ve got constructed a platform that permits speedy coding integrations between devices and apps like LIMS or MES, generates a singular knowledge lake in a harmonized format, and suits modularly into any consumer tech stack—integrating natively with current clouds in AWS or GCP or Azure. This makes knowledge and operations seen to administration and analysis-ready for machine studying or digital twins.”

Ganymede Bio’s knowledge platform is powered by its Lab-as-Code core expertise. It allows scientists and bioinformaticians to jot down their very own real-time integrations and scientific evaluation in a low-code cloud IDE by straight connecting to any lab instrument or scientific software program, shortly bringing whole labs and manufacturing websites onto the cloud. Ganymede Bio additionally presents end-to-end enterprise companies and builds customized integrations for shoppers.

“Ganymede’s velocity and adaptability in integrating devices via Lab-as-Code has been extremely highly effective for us,” mentioned Angelo Stracquatanio, CEO and founding father of Apprentice, certainly one of Ganymede Bio’s earliest companions. 

“We’re proud to be partnering throughout biopharma manufacturing and R&D to get therapeutics to sufferers sooner than ever.”

Losing much less time

“We prefer to say we give superpowers to scientists to allow them to waste much less time on shifting knowledge round and as an alternative spend extra time on analyzing knowledge and deriving novel insights,” mentioned Alan Chramiec, founding scientist of Ganymede Bio. 

“The scientific course of at its core entails piecing collectively knowledge from a number of devices and sources, and we lastly give scientists the device to centralize all their knowledge and automate these efforts. We’re making the lab of the longer term attainable immediately.”

Source link